53 results about "Enterocyte" patented technology

The invention discloses an application of engineered citrobacter freundii in fermentation synthesis of a stable body. The engineered citrobacter freundii is citrobacter freundii overexpressing a polyphosphate kinase gene Ppk1. The stable body prepared by fermenting the engineered citrobacter freundii is rich in polyphosphates and polyamines, particularly, the content of the polyamines can be up to 21wt%, the polyphosphates in the stable body can store the polyamines in an ionic bond combination mode, the combined polyamines are insoluble in water, a natural anion coating is generated, and the stability of the stable body is improved. And the sustained-release tablet is not easily taken by intestinal epithelial cells, so that the sustained-release tablet has a certain sustained-release effect. The medicine prepared by taking the compound as a main active ingredient shows a remarkable curative effect in ulcerative colitis treatment, has the comprehensive effects of reducing oxidative stress, enhancing the anti-inflammatory ability of a body and regulating immunity, is suitable for patients of all ages, and has outstanding application value and market prospect.

The invention discloses an application of a pyrrosia lingua aqueous extract in preparation of a medicine for preventing and treating radioactive intestinal injury. Radioactive intestinal injury is a common complication of ionizing radiation, and has main pathological characteristics of intestinal mucosal barrier destruction, excessive release of inflammatory factors, increase of oxidative stress level and hematopoiesis and immune function inhibition. At present, no effective and safe prevention and treatment medicine is available. It is found for the first time that the pyrrosia lingua aqueous extract can inhibit expression (IL-6, TNF-alpha and IL-1beta) of inflammatory factors of radiation-induced MODE-K cells and relieve the oxidative stress level (malondialdehyde (MDA) is reduced, and the content of superoxide dismutase (SOD) and glutathione (GSH) is increased). In animal experiments, the pyrrosia lingua aqueous extract can reduce the levels of TNF-alpha and IL-1beta inflammatory factors in serum of irradiated mice and improve oxidative stress disorders such as MDA increase, SOD and GSH decrease and the like; the reduction of leukocytes and lymphocytes is relieved; the length of intestinal villus is promoted and recovered; the proportion of Ki67 positive cells in a crypt region is increased, so that the regeneration capacity of intestinal epithelial cells is enhanced. The pyrrosia lingua aqueous extract disclosed by the invention provides an experimental basis and an application prospect for developing a novel medicine for preventing and treating the radioactive intestinal injury.

A probiotic and prebiotic-embedded synbiotic system for targeted delivery and colonization of functions, comprising a probiotic core; an inner layer of protein-polysaccharide / oligosaccharide complex wrapped around the probiotic surface, which acts as both an adhesion promoter, promoting the attachment of probiotics to the intestinal epithelial cells, and as a prebiotic, promoting the growth of probiotics upon release; and an outer layer of a natural emulsifying system on the synbiotic complex, which minimizes water infiltration, thereby effectively embedding and protecting the probiotics. The present synbiotic system is suitable for production in powder form using freeze-drying technology, and is suitable as a dietary supplement or for addition to any food in dry powder form. The system has the ability to bioconvert soy isoflavones and release bioactive phenolic acids from grains to promote body health.

The invention relates to the technical field of functional food preparation, in particular to a composition capable of improving colitis and a preparation method thereof, and the composition comprises glutamine, a composite plant extract, a zinc source and soluble dietary fibers. Wherein the compound plant extract comprises hericium erinaceus extract, ginseng extract and astragalus extract; the zinc source is zinc glycinate, zinc gluconate and the like; the soluble dietary fiber is fructo-oligosaccharide, inulin, galactomannan oligosaccharide and the like. The preparation method comprises the following steps: directly carrying out dry mixing or carrying out fluidized bed granulation on glutamine to obtain particles A, mixing the composite plant extract and the dietary fibers with ethanol, carrying out spray drying to obtain particles B, and carrying out three-dimensional mixing on the particles B and the zinc source. The composition can maintain the homeostasis of intestinal epithelial cells, reduce oxidative stress and inflammatory response, promote mucosal repair and effectively improve ulcerative colitis, Crohn's disease and chemoradiotherapy-related intestinal mucositis through multi-target action.

The invention discloses application of knockout or inhibition of intestinal epithelium Ufbp1 gene expression in preparation of medicines for preventing and / or treating obesity, and belongs to the technical field of biological medicines. In order to solve the problems of limited effect, many side effects and the like of the existing obesity treatment means, the invention provides Ufbp1 specifically expressed by intestinal epithelial cells as a new anti-obesity intervention target for the first time. By knocking out or inhibiting intestinal epithelium Ufbp1, weight gain, adipose tissue accumulation, hyperlipidemia, liver fatty degeneration and insulin resistance induced by high fat diet can be effectively resisted. The action mechanism is related to influence on secretion of intestinal apolipoprotein ApoB48 / ApoA1 and further regulation and control of whole body lipid metabolism. The invention provides a clear target and theoretical basis for developing novel anti-obesity therapies such as small-molecule inhibitors and nucleic acid drugs of targeted intestinal epithelium Ufbp1, and has important clinical transformation prospects.

The invention relates to the technical field of probiotics, in particular to intestinal tract source pediococcus acidilactici of Yanqu county in Tibet and fat reducing application thereof. The pediococcus acidilactici disclosed by the invention is preserved in the China General Microbiological Culture Collection Center on April 29, 2025, and the preservation number is CGMCC NO.34406; the strain has the characteristics of acid resistance, cholate resistance and stress resistance, and has high survival rate and planting efficiency; the strain is free of hemolysis, free of toxic factors and high in safety; the strain can secrete short-chain fatty acid and antibacterial peptide, inhibit pathogenic bacteria and promote intestinal barrier repair; short-chain fatty acid generated by metabolism of most of carbon water by the strain can be directly absorbed by intestinal epithelial cells, and can be used as an energy substance to replace partial glucose demand, so that the metabolism energy consumption is reduced, the energy conversion rate of feed is improved, the feed conversion is promoted, and the effects of reducing fat and weight and improving the non-alcoholic fatty liver disease are achieved.

The application belongs to the technical field of microorganisms, and discloses a propionic acid-producing propionic acid bacteria NHNK-621 and application of the propionic acid bacteria in preparation of products for improving constipation and memory, the bacteria strain has been preserved in the China Center for Type Culture Collection on November 25, 2024, and the number is CCTCC NO: M 20242631. The propionic acid bacteria NHNK-621 provided by the application has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, up-regulating intestinal defensin and mucin gene expression, in addition, the bacterial biofilm can increase the colonization ability to intestinal epithelial cells, and can be used for preparing products for improving constipation and memory.

The present application belongs to the technical field of drug delivery, and relates to a sequential multi-stage targeted delivery system of a probiotic and prebiotic combination for repairing intestinal barriers. The delivery system is a microcapsule MP wrapped with NPs; the NPs are solid lipid nanoparticles formed by wrapping a probiotic with hyaluronic acid coupled small molecule acids as a film material; and the shell material of the microcapsule MP is a prebiotic. By wrapping the probiotic with hyaluronic acid coupled small molecule acids as a film material to form NPs, and then wrapping the NPs with a prebiotic wall material to form a microcapsule, the sequential multi-stage targeting and zonal release of different drugs can be achieved; the repair of the barrier will not have a reverse effect; the intestinal epithelial cell proliferation is promoted to repair the mechanical barrier; the intestinal flora abundance is improved to repair the microbial barrier; the mucus secretion is promoted to repair the chemical barrier; and the immune homeostasis is regulated to repair the immune barrier.

The application discloses a lactobacillus taiwanensis with enhanced intestinal barrier function and application thereof, and belongs to the technical field of microorganisms and medicine. The lactobacillus taiwanensis is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No.63714. The intestinal barrier enhancement and protection of the lactobacillus taiwanensis CCFM1318 are embodied in the following aspects: (1) the lactobacillus taiwanensis CCFM1318 has good in-vitro gastrointestinal tolerance, strong adhesion to intestinal epithelial cells and strong colonization in the gastrointestinal tract; (2) the lactobacillus taiwanensis CCFM1318 significantly up-regulates the expression level of tight junction protein related genes in Caco-2 cells after DSS stimulation; (3) the bacterial-free culture medium supernatant of the lactobacillus taiwanensis CCFM1318 can promote the expression and secretion of MUC2 of the LS 174T goblet cell line, and can improve the expression of MUC2 after endoplasmic reticulum stress, thereby enhancing and protecting the intestinal barrier. The lactobacillus taiwanensis CCFM1318 has great application prospect in products (such as food or medicine) for enhancing and protecting the intestinal barrier.

The invention relates to an in-situ binding method for evaluating binding of Bt toxin Cry1Ac and midgut epithelial cells of cotton bollworm larvae. The method comprises the following steps: incubating and culturing midgut tissues of larvae of lepidoptera pests and a Bt toxin-containing Sf-900 II cell culture solution, carrying out immunostaining, observing and photographing through a laser confocal microscope, and finally carrying out quantitative processing on a fluorescence image by utilizing ImageJ software so as to calculate an average unit area fluorescence signal value. And further evaluating the difference between the binding amounts of the midgut epithelial cells and the Bt toxins of the larvae of different strains. The method can intuitively and accurately observe and evaluate the binding condition of the Bt toxin and the midgut epithelial cells on the premise of retaining the original structure and physiological environment of the midgut tissue of the larvae, provides direct data support for Bt resistance research, assists in analyzing the pest Bt resistance mechanism, has important significance in formulating resistance early warning and treatment strategies, and has a wide application prospect. The method is suitable for the biotechnical fields of Bt toxin insecticidal mechanism research, lepidoptera pest drug resistance mechanism exploration and the like.

The application belongs to the technical field of biological medicine, and particularly relates to application of a CLIC5 gene in preparation of a drug for preventing and / or treating intestinal inflammation. The application provides application of the CLIC5 gene in preparation of a drug for preventing and / or treating intestinal inflammation, wherein a nucleotide sequence of the CLIC5 gene is shown as SEQ ID NO:1. The application finds that intestinal epithelial cell-specific knockout of the CLIC5 can reduce a serum endotoxin level, improve intestinal epithelial barrier function, increase a content of butyric acid, reduce a serum inflammatory factor level, and also reduce a gene expression level of an inflammatory factor in an ileum and a colon. The application first discloses that intestinal epithelial cell-specific knockout of the CLIC5 can effectively prevent or treat intestinal inflammation and reduce a body inflammatory factor level, thereby providing a new target and method for treating human intestinal inflammation.

The invention relates to the technical field of biological medicines, and particularly discloses a method and a composition for promoting intestinal absorption of dihydroquercetin by using quercetin and application of the method and the composition, and the method comprises the following steps: jointly applying an effective amount of dihydroquercetin and an effective amount of quercetin serving as a synergist to an intestinal environment; wherein the quercetin plays a role through at least one of the following mechanisms: inhibiting the function or expression of P-glycoprotein in intestinal epithelial cells; the tight connection of intestinal epithelial cells is regulated. It is found that quercetin not only can effectively inhibit the excretion function of P-glycoprotein in intestinal epithelial cells, but also can enhance the integrity of intestinal barriers by down-regulating the expression level of the protein and up-regulating the expression of tight junction protein, so that intestinal absorption of dihydroquercetin is synergistically promoted from the multi-mechanism level; in addition, the composition can still maintain a good absorption promoting effect in an inflammatory environment, and shows a synergistic anti-inflammatory effect.

The invention relates to the technical field of microorganisms, in particular to leuconostoc mesenteroides subsp.mesenteroides for improving violent eating disorder as well as a product and application of the leuconostoc mesenteroides subsp.mesenteroides. The Leuconostoc mesenteroides subsp. Mesenteroides NHNK-640 is preserved in the China Center for Type Culture Collection on January 8, 2026, and the number of the Leuconostoc mesenteroides subsp. Mesenteroides NHNK-640 is CCTCC (China Center for Type Culture Collection) NO: M 2026046. The Leuconostoc mesenteroides subsp. Mesenteroides NHNK-640 is named as Leuconostoc mesenteroides subsp. Mesenteroides NHNK-640. The leuconostoc mesenteroides subsp. Mesenteroides NHNK-640 provided by the invention can be metabolized to generate kynuric acid, promote intestinal epithelial cells to secrete kynuric acid and reduce diet preference to high-sugar and high-fat foods, and can be used for preparing products for improving violent eating disorder.

The application relates to an oral drug delivery system with a double-emulsion structure and application thereof in preparation of a medicine for treating premature ovarian insufficiency, and belongs to the technical field of biological medicines. The oral drug delivery system comprises an oil-phase solvent, MSCs conditioned medium is wrapped in the inside to form a droplet particle, and exosomes are uniformly distributed on the outer surface of the droplet particle, thereby forming a double-emulsion structure. The water-soluble MSC-CM is wrapped by a water-in-oil-in-water method to form a double-emulsion structure, so that the water-soluble protein is absorbed into the human body in an oral mode. The application has good structural stability and viscoelasticity, the particle size range is about 10-50 mu m, the contact with the intestinal epithelial cells is facilitated, meanwhile, the skeleton of the intestinal epithelial cells can be changed, the expression of the tight junction protein of the intestinal epithelial cells is lowered, the tight junction barrier of the intestinal epithelial cells is opened, and therefore the bioavailability of the MSC-CM is improved, and the role of treating POI is played.

The application belongs to the technical field of genetic engineering, and provides Hsp60 receptor targeted recombinant plant lactobacillus, a construction method and application. The plant lactobacillus is used as a host, pPG612 is used as an expression vector, and CsgB genes or CsgF genes are expressed. Two strains of engineering probiotics can express target proteins and can stably express on the surface of the bacterial body, effectively adhere to AB.9 intestinal epithelial cells, and can inhibit the adhesion and invasion of AB.9 cells. A. veronii Secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the secretion of intestinal mucus IgT. The engineering bacteria can also competitively bind to the Hsp60 receptor of intestinal epithelial cells, down-regulate the expression of p65 through the TLR4 / TLR5 dependent NF-κB signal pathway, inhibit the activation of the NF-κB signal pathway, regulate the redistribution of intestinal tight junction proteins, and down-regulate the expression of pro-inflammatory factors. Furthermore, the engineering bacteria can increase the abundance of intestinal beneficial flora of the snakehead, and the flora can mediate and activate the immune response through the feeding environment.

While studies have been made on a method of selectively inducing differentiation from pluripotent stem cells into enterocyte-like cells, provided is an excellent and high-functionality enterocyte-like cell population that can be stably tested for multi-drug metabolism and permeability, and also provided an efficient method of producing cells. The method of inducing differentiation from pluripotent stem cells into enterocyte-like cells includes the following steps (1) and (2): (1) a step of inducing differentiation from pluripotent stem cells into definitive endoderm cells; and (2) a step of culturing the definitive endoderm cells in a system containing CHIR99021, followed by induction of differentiation into intestinal progenitor cells. A cell population of enterocyte-like cells is more effectively obtained by seeding and culturing enterocyte-like cells produced by the method of inducing differentiation, in a base material for organoid production or a base material for two-dimensional culture.

The present application finds that ITIH4 secreted by macrophages can promote the viability and repair of intestinal epithelial cells, promote the expression of intestinal tight junction protein ZO-1, and inhibit the expression of macrophage inflammatory factors, and is an effective molecule for treating intestinal inflammation. Based on this, the present application provides the use of ITIH4 in the preparation of a medicament for treating intestinal inflammation.

The invention relates to a tetramethyl rhodamine (TAMRA)-labeled agmatine (AGM) fluorescent probe as well as a preparation method and application thereof, and relates to the technical field of biological medicines. A fluorescent group TAMRA is connected with AGM through a solid-phase synthesis method, the high-purity TAMRA-AGM probe is obtained after purification and identification, the high-purity TAMRA-AGM probe has similar biological characteristics with unmodified agmatine, and on the cellular level, the probe can effectively enter various types of intestinal epithelial cells in a short time under the condition of low dosage and is co-located on mitochondria; in a tissue level, the probe can effectively enter intestinal epithelial cells in a body and can carry out visual observation and semi-quantitative analysis on the intestinal epithelial cells; the method realizes visual tracking and accurate positioning of agmatine in cell and tissue levels, provides a key research tool for deeply illuminating the action mechanism of AGM in prevention and treatment of sepsis intestinal injury and other diseases, and has important scientific value and application prospect.

The invention belongs to the technical field of microorganisms and nutriology, and discloses bifidobacterium longum subsp.infantis CICC 6069 for promoting calcium absorption and application of a composition of the bifidobacterium longum subsp.infantis CICC 6069 and vitamin D in improvement of bone health. Cytology experiments and animal models verify that the strain can significantly promote absorption of intestinal epithelial cells to calcium ions and improve the serum calcium level and the calcium apparent absorption rate of calcium-deficient model animals; when the strain is combined with vitamin D, skeletal development (such as increasing bone length and improving bone mineral density) can be further remarkably promoted, and the synergistic effect is remarkably superior to that of single use of the strain. The invention provides an application of bifidobacterium longum infant subCICC 6069 in preparation of related products for promoting calcium absorption, and also provides a composition for promoting calcium absorption and / or improving bone health, and the composition comprises the strain and vitamin D. The invention further provides a preparation method of the bifidobacterium longum infant subCICC 6069 and a preparation method of the bifidobacterium longum infant subCICC 6069. The strain and the composition are suitable for preparing food, health food or medicine for promoting calcium absorption and improving bone health.

The purpose of the present invention is to provide an exosome secretion-promoting composition for promoting exosome secretion from intestinal epithelial cells.　The exosome secretion-promoting composition for promoting exosome secretion from intestinal epithelial cells contains lactic acid bacteria belonging to the genus Fructobacillus, a culture of the lactic acid bacteria, a culture supernatant of the lactic acid bacteria, and / or an extract from the lactic acid bacteria as active ingredients.

It is found that ITIH4 secreted by macrophages can promote intestinal epithelial cell activity and repair, promote expression of intestinal tight junction protein ZO-1 and inhibit expression of macrophage inflammatory factors and is an effective molecule for treating intestinal inflammation. On the basis, the invention provides application of ITIH4 in preparation of a medicine for treating enteritis.

This invention discloses a pharmaceutical composition for alleviating sotorasidib-induced intestinal injury and its uses, belonging to the field of pharmaceutical technology. This invention proposes an intervention strategy to prevent and / or alleviate sotorasidib-induced intestinal injury by activating the cAMP signaling pathway. The cAMP signaling pathway activator can restore PKA activity and / or CREB phosphorylation levels, reduce sotorasidib-induced intestinal epithelial cell apoptosis, improve cell proliferation, and alleviate intestinal barrier damage. This invention also provides a combination of the cAMP signaling pathway activator and sotorasidib for the preparation of antitumor drugs. Cell model verification showed that the combined strategy did not significantly weaken the antitumor effect of sotorasidib, suggesting that this combined strategy has the potential for application as an adjuvant protective measure.

The invention provides a C2BBe1 intestinal cell reprogramming method and system, and aims to solve the technical problems of low reprogramming efficiency, unstable reprogramming result, difficulty in truly simulating in-vivo real conditions and difficulty in driving intestinal epithelial cell physiological morphology and differentiation maintenance in current intestinal tissue modeling. An in-vivo intestinal canal model and an in-vitro gas-liquid exchange interface model are constructed, real in-vivo conditions can be simulated, a crypt-villus topological structure can be reconstructed spontaneously, and spatial heterogeneity and cell lineage distribution of intestinal epithelium can be simulated truly. After specific mechanical stimulation characteristic verification of the intestinal canal at different development stages is carried out, a verification result is obtained, and actual in-vitro inoculation is carried out on the basis of the verification result. And finally undifferentiated cells can be directly reprogrammed, so that the dependence on pluripotent stem cells and a complex induction process in a traditional method is avoided, and the reprogramming efficiency and stability are remarkably improved.

The invention relates to application of a CXCL14 recombinant protein in preparation of a medicine for preventing or treating radiation enteritis, and belongs to the technical field of biomedicine. Excessive inflammation is inhibited by regulating chemotaxis and pro-inflammatory polarization of key immune cells such as macrophages. The CXCL14 recombinant protein directly acts on intestinal epithelial cells and crypt stem cells to promote intestinal villus repair and crypt regeneration, so that the intestinal barrier is structurally recovered. The specific value of intestinal villus length / crypt depth is remarkably increased, and it is proved that the CXCL14 recombinant protein can achieve functional healing instead of symptom relieving.

This invention belongs to the field of genetic engineering technology, specifically relating to a mucosal repair engineered probiotic and its applications. The mucosal repair engineered probiotic constructed in this invention... Escherichia coli The Nissle 1917 expression vector EcN-pBbB8K-CsgA-LFCA-TFF3 links lactoferrin peptide LFCA and trefoil factor 3 TFF3 with EcN-CsgA, enhancing the engineered bacteria's ability to repair Caco-2 intestinal epithelial cells and promoting the proliferation and aggregation of intestinal epithelial cells. This provides an important foundation for the engineered bacteria to establish continuous colonization and cell-cell interaction in the digestive tract environment.

The application discloses a method for preparing recombinant plant lactobacillus over-expressing GAPDH and application thereof, and comprises the following steps: designing specific primers according to the sequence of a GAPDH gene, amplifying a gene fragment containing FLAG; inserting the gene fragment into a constitutive shuttle expression vector pMG36e to construct an in-vitro recombinant expression plasmid; transforming the recombinant expression plasmid into MC1061F competent cells by a heat shock transformation method and then amplifying the recombinant expression plasmid; transforming the amplified recombinant expression plasmid into wild-type competent plant lactobacillus by an electroporation method to prepare the recombinant plant lactobacillus over-expressing GAPDH. E. coli The prepared recombinant plant lactobacillus over-expressing GAPDH is used for improving the speed and capacity of biofilm formation and enhancing the intestinal mucosal adhesion and colonization capacity. In the experiments for determining the biofilm amount and the adhesion of the enterocyte of lateolabrax japonicus, it is proved that the over-expression of GAPDH can enhance the adhesion and colonization capacity of the plant lactobacillus LP-PO23.

The invention provides an oral drug delivery system and application thereof in the field of PAL delivery. According to the invention, DMSN-loaded PAL is taken as a core and is self-assembled with different charged polymers layer by layer through electrostatic interaction, the surface of the core is coated with a multi-layer polymer coating, and then nano-particles are encapsulated by adopting enteric capsules, so that the nano-particles can pass through the stomach to reach the small intestine absorption part in a complete particle form. An oral PAL delivery system which is stable in structure and synergetic in function is constructed. According to the PAL oral delivery system provided by the invention, the resistance of the PAL oral delivery system in intestinal tracts is enhanced, the penetrability of a mucous layer loaded with the PAL is improved, the complex environment in gastrointestinal tracts can be overcome, the PAL oral delivery system is transferred to blood through intestinal epithelial cells to play a role, and good bioavailability and biocompatibility are shown. The method is free of chemical modification, the preparation method is simple, reaction conditions are mild, use of toxic chemical reagents and potential damage to PAL enzyme activity are avoided, and a new PAL administration mode is provided.

The invention belongs to the field of nutriology, and particularly relates to a plant lactobacillus NuPlus-8 capable of synergistically promoting absorption of multiple mineral substances, a product and application. The plant lactobacillus NuPlus-8 disclosed by the invention is derived from healthy breast milk, has good acid-resistant and cholate-resistant characteristics, and can survive and keep activity in related environments of intestinal tracts. The strain has the effect of synergistically promoting absorption of eight nutrient substances including calcium, magnesium, zinc, selenium, iron, phosphorus, vitamin D and protein, and meanwhile promotes skeletal development; phytase can be secreted, phytic acid-mineral compounds can be degraded, combined calcium, magnesium, zinc, selenium, iron and phosphorus can be released, and the solubility and the availability of mineral substances can be improved; and transmembrane transport and absorption of intestinal epithelial cells to various minerals, VD and amino acids are significantly improved. The strain has a unique physiological function of synergistically promoting multi-nutrient absorption, can be used in products for improving nutrient absorption and utilization efficiency, and has remarkable application value and industrial prospect.

The application discloses a high-mucus permeation-cell absorption type soybean polypeptide nanoparticle and a preparation method and application thereof. A soybean protein isolate is subjected to segmented hydrolysis by using a protease and an alkali method, and then coupled with genipin covalent cross-linking to regulate carrier rigidity, so that a high-mucus permeation-cell absorption type soybean polypeptide nanoparticle is obtained. The soybean polypeptide nanoparticle is uniformly dispersed and has high stability, and the apparent permeation coefficient in a mucus layer can be up to 12.01*10 ‑6 cm / s, and the cell uptake amount can be up to 337.63 μg / mg protein, so that the intestinal mucus barrier and the intestinal epithelial cell barrier can be effectively overcome, and the carrier has good delivery characteristics. The application first utilizes segmented hydrolysis by using a protease and an alkali method and coupled with genipin covalent cross-linking to prepare a bio-based nanoparticle with mucus permeation and cell absorption characteristics, and the bio-based nanoparticle can be applied to the fields of functional food, special medical food and medicine as a functional factor / drug delivery carrier.

The application belongs to the field of biological medicine, and discloses a novel targeted delivery system for treating severe ulcerative colitis and application, which comprises the following steps: S101, intracellular gelation process: the Akk bacteria are amplified to the logarithmic growth phase, and after centrifugal resuspension, the bacteria are incubated with BPQDs-NH2 and gel buffer; the components are promoted into cells through a single freeze-thaw cycle; S102, cross-linking reaction: a cross-linking reaction is initiated by using 365nm, 1600mJ / cm² ultraviolet light, and a targeted delivery system GAkk@BP system is obtained through purification. The GAkk@BP oral delivery system constructed in the application has high ROS scavenging capacity, can significantly reduce the intestinal epithelial cell damage induced by ROS, and effectively protect the cell function; in addition, the intracellular gelation modification has realized the precise regulation of Akk proliferation, successfully avoided the risk of excessive colonization, and laid a solid foundation for the subsequent optimization of the intracellular gelation probiotic delivery system, the in-depth analysis of the proliferation blocking / metabolic isolation and the mechanism of the synergistic treatment of UC.